| Mezagitamab | TAK-079 | Phase 3 Clinical | Takeda Pharmaceutical Co Ltd | Autoimmune Diseases; Glomerulonephritis; Glomerulonephritis, IGA; Kidney Diseases; Lupus Erythematosus, Systemic; Multiple Myeloma; Myasthenia Gravis; Nephrosis; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia | 詳細 |
| Daratumumab biosimilar (Celltrion) | CT-P44 | Phase 3 Clinical | Celltrion Inc | | 詳細 |
| Daratumumab biosimilar (Biocad) | BCD-264 | Phase 3 Clinical | BIOCAD JSC | | 詳細 |
| SCTC-21-C | SCTC21C; SCTC-21-C; SCT-C21C | Phase 3 Clinical | SinoCelltech Ltd | Amyloidosis; Autoimmune Diseases; Glomerulonephritis, IGA; Hematologic Neoplasms; Immunoglobulin Light-chain Amyloidosis; Lupus Erythematosus, Systemic; Multiple Myeloma | 詳細 |
| Daratumumab biosimilar (Henlius) | HLX-15 | Phase 3 Clinical | | | 詳細 |
| Recombinant anti-CD38 fully human monoclonal antibody (Henlius Biotech) | | Phase 3 Clinical | | Amyloidosis; Multiple Myeloma | 詳細 |
| Recombinant human anti-CD38 momoclonal antibody(Sumgen) | SG-301; SG301 | Phase 3 Clinical | Hangzhou Shangjian Biotechnology Co Ltd | Hematologic Neoplasms; Lupus Erythematosus, Systemic; Multiple Myeloma; Nephrotic Syndrome | 詳細 |
| STI-6129 | STI-6129; LNDS-1001 | Phase 2 Clinical | Sorrento Therapeutics Inc | Immunoglobulin Light-chain Amyloidosis; Leukemia, Myeloid, Acute; Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours | 詳細 |
| Modakafusp alfa | TEV-48573; TAK-573 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Melanoma; Multiple Myeloma; Neoplasms | 詳細 |
| CLL1/CD33/CD38/CD7 CAR-T cell therapy | | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd | | 詳細 |
| Anti-CD38 Monoclonal Antibody (Genrix) | | Phase 2 Clinical | Genrix (Shanghai) Biopharmaceutical Co Ltd | | 詳細 |
| 4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Autoimmune Diseases; Hematologic Neoplasms; Neuroblastoma | 詳細 |
| REGN-7945 | REGN7945; REGN-7945 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | | 詳細 |
| Anti-CD38 Antibody(Institute of Hematology & Blood Diseases Hospital) | | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Antiphospholipid Syndrome; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia | 詳細 |
| CID-103 | TSK011010; CID-103 | Phase 2 Clinical | Tusk Therapeutics Ltd | Multiple Myeloma; Purpura, Thrombocytopenic, Idiopathic; Rejection of renal transplantation; Thrombocytopenia | 詳細 |
| BHV-1100 | KP-1237; BHV-1100 | Phase 2 Clinical | Biohaven Pharmaceuticals Inc, Kleo Pharmaceuticals, PeptiDream Inc | | 詳細 |
| Lumrotatug | CM-313 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Anemia; Anemia, Aplastic; Blood Platelet Disorders; Glomerulonephritis, IGA; Hematologic Neoplasms; Lupus Erythematosus, Systemic; Lymphoma; Multiple Myeloma; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia | 詳細 |
| 89Zr-DFO-daratumumab | | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | | 詳細 |
| 64Cu-DOTA-daratumumab | | Phase 1 Clinical | City Of Hope National Medical Center | | 詳細 |
| SAR-442257 | SAR-442257 | Phase 1 Clinical | Sanofi | | 詳細 |
| Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | | Phase 1 Clinical | Shengyan Pharmaceutical Technology | | 詳細 |
| dual anti-BCMA/anti-CD38 CAR T-cell therapy (Shengyan Pharmaceutical Technology/Tongji Medical College) | | Phase 1 Clinical | Tongji Medical College | | 詳細 |
| CD38 CAR T-cells | | Phase 1 Clinical | Zhejiang University | Hematologic Neoplasms; Leukemia, Myeloid, Acute | 詳細 |
| anti-CD38 CAR T-cell therapy (Shanghai Unicar-Therapy Bio-Medicine Technology/Soochow University/East China Normal University) | | Phase 1 Clinical | Soochow University | | 詳細 |
| actinium-225 labeled daratumumab (Actinium Pharmaceuticals) | | Phase 1 Clinical | Actinium Pharmaceuticals Inc, City Of Hope National Medical Center, National Cancer Institute | Hematologic Neoplasms; Multiple Myeloma | 詳細 |
| T-007 (TNK Therapeutics/Celularity) | | Phase 1 Clinical | Tnk Therapeutics Inc | | 詳細 |
| Anti-CD38 chimeric antigen receptor T cell therapy(Yake Biotechnology) | CAR-T CD-38 | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Leukemia, Myeloid, Acute; Multiple Myeloma | 詳細 |
| Indium In 111-DOTA-Daratumumab | | Phase 1 Clinical | City Of Hope National Medical Center | Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 詳細 |
| Daratumumab biosimilar (Jushi Biopharma) | | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | | 詳細 |
| CD38\CS1 Chimeric Antigen Receptor T Cells therapy(The Second Hospital Of Shandong University) | | Phase 1 Clinical | The Second Hospital Of Shandong University | | 詳細 |
| SAR-444559 | SAR444559; SAR-444559 | Phase 1 Clinical | Sanofi | | 詳細 |
| 68Ga-NB-381 | 68Ga-NB381; 68Ga-NB-381; 18F-FDG(The First Affiliated Hospital Of Beijing University) | Phase 1 Clinical | The First Affiliated Hospital Of Beijing University | | 詳細 |
| Dual CLL1/CD38 targeting CAR-T cell therapy (Gracell Biotechnologies) | | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | | 詳細 |
| Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | | 詳細 |
| RB-0021 | RB0021; RB-0021 | Phase 1 Clinical | Ruiyang (Suzhou) Biological Technology Co Ltd | Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma | 詳細 |
| KJ-C2320 | KJ-C2320 | Phase 1 Clinical | CARsgen Therapeutics Holdings Ltd | | 詳細 |
| Daratumumab biosimilar (Hangzhou Jiuyuan Gene Engineering) | JY43; JY-43 | Phase 1 Clinical | Hangzhou Jiuyuan Gene Biomedical Co Ltd | | 詳細 |
| KYS202002A | KYS-202002A; KYS202002A | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Lupus Erythematosus, Systemic; Multiple Myeloma | 詳細 |
| ISB-2001 | ISB-2001; ABBV-2001 | Phase 1 Clinical | Ichnos Sciences Sa | | 詳細 |
| TNB-738 | TNB-738 | Phase 1 Clinical | TeneoFour Inc | | 詳細 |
| GBR-1342 | GBR-1342; ISB-1342 | Phase 1 Clinical | Glenmark Pharmaceuticals Ltd | | 詳細 |
| XmAb-968 | XmAb968 | Phase 1 Clinical | Xencor Inc | Hematologic Neoplasms; Leukemia, Promyelocytic, Acute | 詳細 |
| XmAb-18968 | XmAb-18968 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | | 詳細 |
| 211At-OKT10-B10 | | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | | 詳細 |
| Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | Y-150; Y150 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd, Wuhan Yzy Biopharma Co Ltd | | 詳細 |
| Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics) | | Phase 1 Clinical | Celularity Inc, Sorrento Therapeutics Inc | | 詳細 |
| SAR-442085 | SAR-442085 | Phase 1 Clinical | Sanofi | | 詳細 |
| 111Indium labeled daratumumab | | | City Of Hope National Medical Center, National Cancer Institute | | 詳細 |